<DOC>
	<DOCNO>NCT00424502</DOCNO>
	<brief_summary>This single arm study evaluate efficacy safety MabThera patient active rheumatoid arthritis whose current treatment one TNF blocker produce inadequate response . Patients receive MabThera ( 1g infusion ) day 1 day 15 , continue basic methotrexate therapy ( 10-25mg/week ) . The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study MabThera ( Rituximab ) Patients With Rheumatoid Arthritis Who Have Had Inadequate Response TNF-Blocker .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; diagnose RA &gt; =3 month prior first administration study medication ; inadequate response intolerance &gt; =1 antiTNF therapy , alone combination methotrexate ; use NSAIDS , analgesic oral corticosteroid , must stable dose &gt; =2 week prior start study . chronic inflammatory disease ; use parental corticosteroid within 4 week prior screen ; severe heart failure , severe , uncontrolled cardiac disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>